CORC

在结果中检索

CORC

浏览/检索结果: 共79条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study 期刊论文
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 卷号: 34, 期号: 1
作者:  Robertson, Michael N.;  Wei, Lai;  Jia, Ji Dong;  Wang, Fu Sheng;  Niu, Jun Qi
收藏  |  浏览/下载：27/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05
Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans 期刊论文
Clinical Infectious Diseases, 2019, 卷号: Vol.68 No.5, 页码: 857-859
作者:  Adeel A Butt;  Peng Yan;  Vincent Lo Re III;  Obaid S Shaikh;  David B Ross
收藏  |  浏览/下载：15/0  |  提交时间：2019/12/17
HCV  treatment  cascade  DAA  ERCHIVES  HCV  treatment  uptake  
Sam68 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 2 of Viral 5 \' Untranslated Region 期刊论文
JOURNAL OF VIROLOGY, 2019, 卷号: Vol.93 No.14
作者:  Qin, YW;  Xun, Z;  Guo, YX;  Chen, SW;  Zhu, HZ
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/17
A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens 期刊论文
2019, 卷号: 116, 页码: 108976
作者:  Li, Hu;  Tan, Jia-Li;  Li, Jian-Rui;  Liu, Nan-Nan;  Chen, Jin-Hua
收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace